European Committee for Treatment and Research in Multiple Sclerosis Congress (ECTRIMS)

The professor of neurology at the University of Colorado posited that if certain criteria are met, it could be appropriate to take patients with multiple sclerosis off of DMT.

Data from multiple open-label extension trials have suggested that the therapy is more beneficial with earlier initiation compared to interferon ß-1a.

Three new multiple sclerosis studies show the promise of two drugs, amiselimod and alemtuzumab, as treatments and one, arbaclofen, for spasticity.

Our Sept. news includes a possible clinical marker and therapy target in Alzheimer disease and MS findings from an optical coherence tomography study.

This ECTRIMS session includes studies using 7T and 3T MRI images and translocator protein PET scans, as well as phenotypes in gray matter and more.

Research presented at this ECTRIMS session covered management of multiple sclerosis-related fatigue, cognitive issues, and gait impairment.

Hot Topics session at ECTRIMS 2016: treat early active RRMS with potent induction therapy or immunomodulation then escalation? Where do you stand?

The session featured a study comparing MRI criteria for diagnosing MS, the role of spinal cord volume loss in predicting disease activity, and more.